Pfizer, BioNTech Launch Phase 1 Study Of Combo COVID And Flu Vax

Pfizer and BioNTech are the latest companies to begin studying a combination COVID-19-flu vaccine, BioNTech announced Thursday (Nov. 3) as public health officials warn of a potential “tripledemic” -- a combination of severe flu, respiratory syncytial virus (RSV) and continued COVID-19 cases -- this fall. Moderna and Novavax also have ongoing studies on their respective combination COVID-19 and flu vaccines. Pfizer and BioNTech’s vaccine candidate combines Pfizer’s quadrivalent modified mRNA-based flu vaccine, and the two companies’ bivalent COVID-19 shot. The...